{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:24:10Z","timestamp":1771493050636,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gynecologic Oncology Group Statistical Office","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}]},{"name":"NRG Oncology","award":["1U10 CA180822"],"award-info":[{"award-number":["1U10 CA180822"]}]},{"name":"NRG Operations","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ygyno.2016.09.005","type":"journal-article","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T01:51:07Z","timestamp":1475286667000},"page":"511-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"143","author":[{"given":"Peter G.","family":"Rose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Java","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles","family":"Alvarez-Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua P.","family":"Kesterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick B.","family":"Stehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Warshal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Creasman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parviz","family":"Hanjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.09.005_bb0005","first-page":"646","article-title":"A drug's life: the pathway to drug approval","volume":"11","author":"Keng","year":"2013","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0010","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1200\/JCO.2005.05.017","article-title":"Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival","volume":"23","author":"Berger","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0015","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.ejca.2011.06.014","article-title":"Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients","volume":"47","author":"Kong","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.09.005_bb0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11912-013-0297-5","article-title":"Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy","volume":"15","author":"Nelson","year":"2013","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0025","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1158\/1078-0432.CCR-13-0916","article-title":"Neoadjuvant therapy as a platform for drug development and approval in breast cancer","volume":"19","author":"Bardia","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0030","doi-asserted-by":"crossref","first-page":"632.e1-8","DOI":"10.1016\/j.ajog.2014.06.034","article-title":"Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer","volume":"211","author":"Petrillo","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0035","series-title":"An Analysis of the Neoadjuvant Arm of Chorus","article-title":"Response after 3cycles of first line platinum chemotherapy in advanced ovarian cancer","author":"Kehoe","year":"2016"},{"key":"10.1016\/j.ygyno.2016.09.005_bb0040","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","article-title":"Role of surgery in ovarian carcinoma","volume":"25","author":"Fader","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0045","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0050","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"50","key":"10.1016\/j.ygyno.2016.09.005_bb0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/14786440009463897","article-title":"On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling","volume":"5","author":"Pearson","year":"1900","journal-title":"Philos. Mag. Ser."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of ranks in one-criterion variance analysis","volume":"47","author":"Kruskal","year":"1952","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0070","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2015"},{"key":"10.1016\/j.ygyno.2016.09.005_bb0075","first-page":"257","article-title":"An interim report on the second look procedure for cancer of the stomach, colon, and rectum and for limited intraperitoneal carcinosis","volume":"99","author":"Wangensteen","year":"1954","journal-title":"Surg. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0080","first-page":"1085","article-title":"The second look operation for carcinoma of the ovary","volume":"131","author":"Wallach","year":"1970","journal-title":"Surg. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0085","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/1097-0142(197609)38:3<1438::AID-CNCR2820380351>3.0.CO;2-2","article-title":"Second-look operation in ovarian carcinoma: post chemotherapy","volume":"38","author":"Smith","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.09.005_bb0090","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ygyno.2005.05.012","article-title":"Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study","volume":"99","author":"Greer","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0105","first-page":"213","article-title":"Analysis of failures and clinical outcome of advanced epithelial ovarian cancer in patients with microscopic residual disease at second-look reassessment following primary cytoreductive surgery and first-line platinum-based chemotherapy","volume":"34","author":"Gadducci","year":"2013","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2001.6246","article-title":"Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy","volume":"82","author":"Rose","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"55 Suppl","key":"10.1016\/j.ygyno.2016.09.005_bb0115","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1200\/jco.2015.33.15_suppl.5563","article-title":"Use of neoadjuvant chemotherapy in advanced ovarian cancer","volume":"33","author":"Meyer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0360-3016(95)00252-9","article-title":"Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study","volume":"34","author":"Randall","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0130","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1245\/s10434-015-5030-1","article-title":"Impact of tumor size on probability of pathologic complete response after neoadjuvant chemotherapy","volume":"23","author":"Baron","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2016.04.033","article-title":"Mutations in homologous recombination genes and response to treatment in GOG 218: an NRG Oncology study","author":"Norquist","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.09.005_bb0140","series-title":"San Antonio Breast Cancer Symposium","article-title":"Recombination Deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple-negative breast cancer (TNBC): a pooled analysis","author":"Telli","year":"2015"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816313683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816313683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T05:22:59Z","timestamp":1568438579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816313683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0090825816313683"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.09.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}